Galderma, a skincare company that also has an R&D pipeline, is set to start trading on the SIX Swiss Exchange Friday at a premium price of CHF 53 ($59.31) per share, placing its IPO value at CHF 2.3 billion ($2.6 billion).
The Zug-based entity is mainly known for consumer brands such as Cetaphil and Differin. Last week, Galderma said it planned to price its public debut between CHF 49 to CHF 53 apiece. The shares will be listed as “GALD” on Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.